GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies

AF Leal, E Benincore-Flórez, D Solano-Galarza… - International journal of …, 2020 - mdpi.com
GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside
accumulation into the lysosome due to mutations on the genes encoding for the β …

Less is more: substrate reduction therapy for lysosomal storage disorders

MF Coutinho, JI Santos, S Alves - International journal of molecular …, 2016 - mdpi.com
Lysosomal storage diseases (LSDs) are a group of rare, life-threatening genetic disorders,
usually caused by a dysfunction in one of the many enzymes responsible for intralysosomal …

Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

N Giladi, RN Alcalay, G Cutter, T Gasser… - The Lancet …, 2023 - thelancet.com
Background Variants in the GBA1 gene, which encodes lysosomal acid glucocerebrosidase,
are among the most common genetic risk factors for Parkinson's disease and are associated …

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease

M Huebecker, EB Moloney, AC van der Spoel… - Molecular …, 2019 - Springer
Abstract Background Haploinsufficiency in the Gaucher disease GBA gene, which encodes
the lysosomal glucocerebrosidase GBA, and ageing represent major risk factors for …

Novel activity-based probes for broad-spectrum profiling of retaining β-exoglucosidases in situ and in vivo

WW Kallemeijn, KY Li, MD Witte… - Angewandte Chemie …, 2012 - research.rug.nl
Cyclophellitol aziridine-type activity-based probes allow for ultra-sensitive visualization of
mammalian β-glucosidases (GBA1, GBA2, GBA3, and LPH) as well as several non …

New strategies for the treatment of lysosomal storage diseases

G Parenti, C Pignata, P Vajro… - … journal of molecular …, 2013 - spandidos-publications.com
The lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders caused
by the deficiency of any of the lysosomal functions, in most cases of lysosomal hydrolases …

Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses

MJ Ferraz, WW Kallemeijn, M Mirzaian, DH Moro… - … et Biophysica Acta (BBA …, 2014 - Elsevier
Gaucher disease (GD) and Fabry disease (FD) are two relatively common inherited
glycosphingolipidoses caused by deficiencies in the lysosomal glycosidases …

[HTML][HTML] Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease

JMFG Aerts, CL Kuo, LT Lelieveld, DEC Boer… - Current opinion in …, 2019 - Elsevier
Glycosphingolipids are important building blocks of the outer leaflet of the cell membrane.
They are continuously recycled, involving fragmentation inside lysosomes by glycosidases …

Inhibition of lysosome membrane recycling causes accumulation of gangliosides that contribute to neurodegeneration

M Boutry, J Branchu, C Lustremant, C Pujol, J Pernelle… - Cell reports, 2018 - cell.com
Lysosome membrane recycling occurs at the end of the autophagic pathway and requires
proteins that are mostly encoded by genes mutated in neurodegenerative diseases …

Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling

M Fan, R Sidhu, H Fujiwara, B Tortelli, J Zhang… - Journal of lipid …, 2013 - ASBMB
Niemann-Pick type C (NPC) 1 is a rare neurodegenerative disease for which treatment
options are limited. A major barrier to development of effective treatments has been the lack …